Migraine STImulation Crisis of Migraine

NCT ID: NCT04568252

Last Updated: 2023-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-04

Study Completion Date

2023-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Migraine is a neurovascular disease whose prevalence is estimated at almost 20% of the adult population. Currently, there is no treatment for migraine.

Millimeter stimulation of the wrist subcutaneous receptors allows the release of endorphin in the brain.

MISTIC is a prospective, controlled, multicenter, double-blind, randomized study in which the research team are investigating whether millimeter stimulation of subcutaneous wrist receptors reduces the frequency of migraine crisis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MISTIC is a multicenter, controlled, randomized, double-blind study. Eligible patients will have to report their migraine crisis in a diary during a one month pre-selection phase. Then, patients will be randomized into one of two treatment groups :

* active millimeter wave emission bracelet
* or placebo bracelet

Patients will have to use the medical device twice a day for 3 months. The investigators will follow them for an additional 3 months to assess the persistence of the effect.

Throughout the follow-up, patients will report their migraines crisis in a journal.

The primary outcome will be the impact of wearing a millimeter wave bracelet for 3 months, on the number of days with migraine headaches.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Without Aura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomization : intervention group and control group
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Millimetric wave emission bracelet.

Group Type EXPERIMENTAL

Wristband with millimeter wave emission.

Intervention Type DEVICE

Wristband treatment with millimeter wave emission twice a day for 3 months.

Control

Placebo bracelet.

Group Type SHAM_COMPARATOR

Placebo of wristband with millimeter wave emission.

Intervention Type DEVICE

Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wristband with millimeter wave emission.

Wristband treatment with millimeter wave emission twice a day for 3 months.

Intervention Type DEVICE

Placebo of wristband with millimeter wave emission.

Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with episodic migraine without aura (according to ICDH3 classification criteria)
* Patient with at leat 4 migraine days per month and no more than 8 migraine days per months
* Background treatment (or not) stable for at least 1 month
* Drug management of migraine stable for at least one month
* Non-drug management of stable migraine at least 1 month prior to the study
* Patient affiliated to social security or beneficiary of such a scheme

Exclusion Criteria

* Patients with chronic migraine (defined according to IHS criteria)
* Patients already included in an interventional clinical research protocol
* Patients with chronic headache due to drug abuse (according to IHS criteria)
* Patients with only migraine crisis with aura
* Wrist size \< 14.5 and \> 21 cm
* Situations of dermatological pathologies on pre-existing wrists (oozing dermatosis, hyper sweating, eg.) or unhealed lesions on both wrists.
* Presence of metallic object (bracelet, watch, piercing...) on both wrists.
* Presence of a tattoo on both wrists
* Allergic reactions on contact with silicone or metal
* Persons referred to in Articles L 1121-5 to L 1121-8 of the CSP (corresponds to all protected persons) pregnant women, parturient women, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure
* Women of childbearing age with a short-term pregnancy project
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Remedee SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Caroline MD MAINDET

Role: PRINCIPAL_INVESTIGATOR

CHUGA, 38000 Grenoble

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Grenoble Alpes

Grenoble, , France

Site Status

Cabinet Mornant

Mornant, , France

Site Status

CH Fondation Rotschild

Paris, , France

Site Status

Cabinet Saint Ismier

Saint-Ismier, , France

Site Status

Cabinet Neuralpes

Saint-Martin-d'Hères, , France

Site Status

CH Voiron

Voiron, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MISTIC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Magnetic Therapy in Migraine Prophylaxis
NCT00901862 COMPLETED PHASE1
A Study of Wearable Devices to Predict Migraines
NCT05755945 ENROLLING_BY_INVITATION NA
Bronx MBCT-Migraine
NCT02443519 COMPLETED NA
Transnasal Cooling for Migraine
NCT04936061 TERMINATED NA
Migraine Prevention Using ActiPatch
NCT03166046 COMPLETED NA